Compare LCTX & CLDT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LCTX | CLDT |
|---|---|---|
| Founded | 1990 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 366.2M | 362.9M |
| IPO Year | 1996 | N/A |
| Metric | LCTX | CLDT |
|---|---|---|
| Price | $1.95 | $7.83 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | $4.67 | ★ $9.50 |
| AVG Volume (30 Days) | ★ 1.2M | 225.4K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | ★ 4.86% |
| EPS Growth | ★ 25.00 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $9,499,000.00 | N/A |
| Revenue This Year | $6.32 | $1.39 |
| Revenue Next Year | $124.49 | N/A |
| P/E Ratio | ★ N/A | $610.21 |
| Revenue Growth | ★ 6.19 | N/A |
| 52 Week Low | $0.37 | $5.83 |
| 52 Week High | $2.09 | $8.47 |
| Indicator | LCTX | CLDT |
|---|---|---|
| Relative Strength Index (RSI) | 64.30 | 65.99 |
| Support Level | $1.55 | $6.84 |
| Resistance Level | $2.04 | N/A |
| Average True Range (ATR) | 0.11 | 0.22 |
| MACD | 0.02 | -0.01 |
| Stochastic Oscillator | 89.04 | 97.73 |
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cells transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.
Chatham Lodging Trust is a U.S.-based real estate investment trust that invests in upscale extended-stay hotels. The firm operates across various states in the U.S., including California, New York, Texas, Florida, Minnesota, Massachusetts, and Pennsylvania among others. Substantially all of the company's assets are held and operated by its Operating Partnership, Chatham Lodging, LP. Chatham Lodging LP and its subsidiaries lease the overall company's hotels. The firm operates through a single segment because of the similar economic characteristics of its hotels. Chatham's revenue streams include Room, Food and beverage, and Other. Room comprises the majority of total revenue. Chatham's hotels operate under brands which include, Hilton, Marriott, and Hyatt.